Summary Somatostatin is a regulatory peptide implicated in the control of cellular proliferation in epithelial tissues and this regulation may occur directly via membrane bound receptor activation. The aim of this study was to investigate somatostatin binding in human gastrointestinal cancer and normal mucosa. Plasma membranes were prepared from specimens of tumour and normal mucosa from 51 patients undergoing surgical resection for malignancy (28 gastric, 23 (Horowitz et al., 1975; Higgins et al., 1941; Crile, 1957; Osei et al., 1985) . There is, however, no currently defined role for endocrine therapy in non-endocrine gastrointestinal cancer. Surgical intervention is the most effective treatment for this condition and, even then, can only afford a 'cure' in early disease. Advanced tumours are associated with a poor prognosis, marginally improved by chemotherapeutic regimens. Any benefit from systemic therapy is usually abrogated by systemic toxicity (Rake et al., 1979; Engstrom et al., 1985; Bleiberg, 1990) . For this reason a non-toxic, effective, treatment modality would be of value to improve the outlook for those patients with advanced disease.
Hormonal manipulation, by surgical or medical methods, has been used extensively in therapy for carcinoma of the breast, prostate, thyroid and in certain gut endocrine tumours (Horowitz et al., 1975; Higgins et al., 1941; Crile, 1957; Osei et al., 1985) . There is, however, no currently defined role for endocrine therapy in non-endocrine gastrointestinal cancer. Surgical intervention is the most effective treatment for this condition and, even then, can only afford a 'cure' in early disease. Advanced tumours are associated with a poor prognosis, marginally improved by chemotherapeutic regimens. Any benefit from systemic therapy is usually abrogated by systemic toxicity (Rake et al., 1979; Engstrom et al., 1985; Bleiberg, 1990) . For this reason a non-toxic, effective, treatment modality would be of value to improve the outlook for those patients with advanced disease.
There is increasing evidence that tumours arising from the gastrointestinal tract are, at least in part, hormone dependent. Numerous hormones have now been implicated in the pathogenesis and development of gastrointestinal malignancy, including gastrin, epidermal growth factor, enteropancreatic hormones and oestrogenic steroids (Sirinek et al., 1985; Watson et al., 1988; Li et al., 1980; Howatson & Carter, 1985; McMichael et al., 1980) . These findings, together with the observation that transformed gut epithelial cells may retain functional hormone receptors , have suggested a role for hormonal manipulation in these malignancies.
Somatostatin and its analogues are good candidates for use as endocrine agents in the treatment of gastrointestinal cancer. The native peptide is widely distributed in the body and, amongst its many inhibitory actions, has a putative role as an anti-proliferative agent in both normal (Lehy et al., 1979) and malignant tissue. The mechanisms involved in this anti-proliferative action have not, as yet, been confirmed. Both the native peptide and its analogues act at the somatotrophs of the anterior pituitary suppressing growth hormone production and release (Adrian et al., 1981) . This may influence the proliferation of target tissues directly or may result in a substantial reduction in local growth factor release (Kirkegaard et al., 1984 (Reubi et al., 1987a; Reubi et al., 1987b; Reubi et al., 1990; Ikuyama et al., 1985) . Somatostatin Srikant and Patel (1981) . In brief, frozen tumour and mucosal samples were mechanically pulverised and homogenised on ice in homogenising buffer (sucrose 250 mM, KCI 25 mM and MgCl2 10 mM in Tris-HCI 50 mM; pH 7.4) at 10,000 r.p.m. in short bursts for 2 min using an Ultraturrax T25 homogeniser (Scientific Instruments Ltd, Liverpool, UK). The homogenate was centrifuged at 4°C at 270 g for 10 min to remove nuclear debris and the supernatant retained. This crude membrane suspension was then ultracentrifuged at 4°C for O min at 15,000 g using a Beckmann L5 65B Ultracentrifuge (Beckmann Laboratory Instruments, High Wycombe, Bucks, UK). The pellet was resuspended in Tris-HCl buffer (Tris-HCl 10 mM, pH 7.4) and ultracentrifuged for O min at 15,000g. The final pellet was resuspended in 2 ml of the Tris-HCl buffer, pH 7.4, and the protein content determined after the method of Bradford (1976) .
Rat cerebral cortex was used as a positive control for all binding assays. Six week old female Wistar rats were sacrificed by cervical dislocation and the cerebral hemispheres dissected from the remaining cranial contents. Plasma membranes were prepared as outlined above and used at a final protein concentration of 0.2 mg ml-'.
Preparation of '25I-tyr-J -somatostatin-14 Iodination of tyr-11-somatostatin-14 (Sigma Ltd, UK) was performed using the Chloramine T method (Czernick & Petrack, 1983 ). The iodination reaction mixture was eluted on a G-25 Superfine Sephadex column using an elution buffer of 0.1 M acetic acid containing mg ml-' bovine serum albumin. Eluted fractions were collected and the specific activity of the combined '25I-tyr-l 1-somatostatin-14 peak was calculated to be between 330 and 500Cimmol-1.
Demonstration of somatostatin binding A twelve point competitive displacement assay was developed and validated using plasma membranes prepared from rat cerebral cortex. Incubation buffer (HEPES3-KOH 50 mM, MgCl2 10 mM, BSA 1% and bacitracin 0.01%; pH 7.4), 50 ,ul, was added to each reaction tube. Unlabelled somatostatin-14 (Sigma Ltd, UK) was then added in 10 aliquots over the concentration range 10-1 M to 10-M. Total binding was assessed by the addition of 10 t l I of 50 mM HEPES-KOH pH 7.4. An aliquot of 20 t l I of plasma membrane preparation at a protein concentration of 1-1.5 mg ml-' was added to the reaction tubes. Finally 20 ,ul (100,000 c.p.m.) of radioisotope (approx 2 nM) was added to each tube. Samples were incubated for 1 h at 35°C, the reaction being stopped by the addition of 0.5 ml ice cold saline, and centrifugation at 13,000 g for 2 min in a Microcentaur microcentrifuge (MSE Ltd, UK). The supernatant was removed by suction, the pellet washed once with 0.5 ml ice cold saline and counted in the reaction tube on a Packard Cobra II Autogammacounter (Canberra Packard, Pangbourne, Berks, UK). All assay points were performed in triplicate and the coefficient of variation of the triplicates was less than 10%. Fielding et al., 1983) .
Data analysis and statistical methods Binding data was processed using the Ligand PC Curve Fitting Program (Munson & Rodbard, 1980) (Figure 1 ). These findings are consistent with those reported previously (Srikant & Patel, 1981; Reubi & Maurer, 1986 Table I , along with the binding characteristics. There was no relationship between any of the tumour characteristics and somatostatin binding.
Discussion
The current report represents the first systematic examination of somatostatin binding in solid neoplasms of the gastrointestinal tract. We have demonstrated high levels of specific binding for this peptide in membrane preparations from the majority of human colorectal and gastric cancers, and that these binding sites are also present in normal mucosa. The binding in both malignant tissue and uninvolved mucosa is normally low affinity, with a Kd usually in the micromolar range, in contrast to the high affinity binding site we demonstrate in rat cerebral cortex. One gastric tumour, however, in repeated determinations, consistently exhibited a high affinity binding site indicating that this tissue expresses a different class of receptor. Interestingly, the binding in the adjacent normal mucosa in this patient was of the normal, low affinity, type which we characteristically demonstrate in mucosa.
The demonstration of low affinity binding in normal gastric mucosa may seem at variance with reports of somatostatin binding in isolated parietal cell preparations (Sjodin et al., 1990; Reyl-Desmars & Lewin, 1982) , although species variations and differences in ligand (Conlon et al., 1981) make comparisons difficult. However, it is possible that high affinity binding, which may be found in certain cell population in the mucosa, is not being detected by our technique which employs a whole tissue membrane preparation. It is of interest that Reubi and Maurer (1986) have demonstrated a low affinity receptor site in rat cerebral cortex, although this 'low affinity' site has a much higher affinity than that which we have identified.
In many receptor binding systems, it is assumed that functioning receptors require high ligand affinity such that optimum binding can occur at physiological hormone concentrations. That only one tumour of 51 assayed should express such high affinity receptor sites for somatostatin may seem disappointing since it implies that therapy based upon long-acting somatostatin analogues may be of benefit in a very small minority of patients. The incidence of high affinity receptors for other hormones, such as gastrin, in colonic carcinoma has been reported as 50-60% (Upp et al., 1989) . Thus, gastrin antagonist therapy may be a reasonable therapeutic modality in receptor positive cases. However, the physiological and functional significance of such low affinity somatostatin binding is less easily evaluated.
One possible explanation for the function of a low affinity receptor is that it may be involved in local regulation, in an autocrine or paracrine fashion, as opposed to a true endocrine mechanism. Low circulating levels of somatostatin may be functionally insignificant whilst high local levels within the mucosa/tumour may be active. These findings are of importance if therapy based on the natural anti-proliferative effects of somatostatin is to be considered. Clearly, the native peptide cannot be used as a pharmacologically useful agent since its half life in the circulation is less than 3 min. However, current analogues of somatostatin, which are based upon a cyclic octapeptide sequence, have been found to have times the suppressive effect on growth hormone release of native somatostatin with biological half lives of 3-6 h (Cai et al., 1986) . Thus, used in pharmacological doses, appropriately designed analogues may be expected to have significant effects on low affinity receptors.
The results of our studies do not directly tell us whether somatostatin analogues will be of value in gastrointestinal cancer since firstly, the functional significance of the binding we have demonstrated is not clear and, secondly, somatostatin may exert growth effects independently of its interaction with membrane bound receptors on tumour cells. The direct, receptor mediated effects of somatostatin on cell growth appear to relate to the dephosphorylation of intracellular phosphoproteins . It is known that EGF stimulates cell growth by inducing phosphorylation of these residues and, as a corollary, somatostatin induced dephosphorylation has been suggested to correlate with inhibition of EGF stimulated cell growth in certain cancer cell lines (Liebow et al., 1989; Hierowski et al., 1985) . Further studies, including examination of second messenger activation and affinity labelling may elucidate the therapeutic potential of the interaction between somatostatin and low affinity binding sites in human gastrointestinal cancer.
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